Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee stock options have a 10-year term.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted stock options covering 261,300 shares to ten new employees, effective November 2, 2026.
The options have an exercise price of $7.07 per share, equal to the last reported Nasdaq sale price on November 2. Approved by the board’s Compensation Committee under the 2022 Inducement Plan, the awards were employment inducements under Nasdaq Listing Rule 5635(c)(4). They vest over four years: 25 percent on the first anniversary of each employee’s vesting commencement date, followed by 36 equal monthly installments, subject to continued employment.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 261,300 shares at $7.07 per share create potential dilution if exercised.
Key Figures
- Options granted
- 261,300 shares
- Granted to ten new employees
- Recipients
- 10 employees
- New employees receiving stock options
- Exercise price
- $7.07 per share
- Equal to the November 2 last reported sale price
- Option term
- 10 years
- Stock option term
- Vesting schedule
- 25% at the first anniversary; remainder in 36 equal monthly installments
- Four-year vesting, subject to continuous employment
Historical Context
-
Earlier grant covered six employees under same plan, with four-year vesting and a 10-year term.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to ten new employees to purchase an aggregate of 261,300 shares of the Company's common stock, effective as of November 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options did Olema Oncology grant to new employees?
Olema granted ten new employees options to purchase an aggregate of 261,300 common shares, effective November 2, 2026. The exercise price is $7.07 per share, equal to the last reported Nasdaq sale price on that date.
How do Olema Oncology’s November 2026 inducement options vest?
The options vest over four years, subject to continued employment on each vesting date. Twenty-five percent vests on the first anniversary of each employee’s vesting commencement date, with the remainder vesting in 36 equal monthly installments over the following three years.